MX343894B - Síntesis y uso de inhibidores de cinasa. - Google Patents
Síntesis y uso de inhibidores de cinasa.Info
- Publication number
- MX343894B MX343894B MX2012014986A MX2012014986A MX343894B MX 343894 B MX343894 B MX 343894B MX 2012014986 A MX2012014986 A MX 2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A MX 343894 B MX343894 B MX 343894B
- Authority
- MX
- Mexico
- Prior art keywords
- synthesis
- fak
- based catalyst
- kinase inhibitors
- reactions
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 4
- 238000006243 chemical reaction Methods 0.000 abstract 3
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 229910052763 palladium Inorganic materials 0.000 abstract 2
- 150000001448 anilines Chemical class 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001502 aryl halides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35994210P | 2010-06-30 | 2010-06-30 | |
| PCT/US2011/042169 WO2012012139A1 (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012014986A MX2012014986A (es) | 2013-07-03 |
| MX343894B true MX343894B (es) | 2016-11-28 |
Family
ID=45497129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014986A MX343894B (es) | 2010-06-30 | 2011-06-28 | Síntesis y uso de inhibidores de cinasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9505719B2 (enExample) |
| EP (1) | EP2588476A4 (enExample) |
| JP (1) | JP5923499B2 (enExample) |
| CN (1) | CN103168037A (enExample) |
| AU (1) | AU2011280031B2 (enExample) |
| CA (1) | CA2803005A1 (enExample) |
| MX (1) | MX343894B (enExample) |
| NZ (1) | NZ604801A (enExample) |
| WO (1) | WO2012012139A1 (enExample) |
| ZA (1) | ZA201300012B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
| CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656182A (en) * | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US20040006005A1 (en) | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AU1167702A (en) | 2000-10-11 | 2002-04-22 | Cephalon Inc | Compositions comprising modafinil compounds |
| TW200409629A (en) * | 2002-06-27 | 2004-06-16 | Bristol Myers Squibb Co | 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| CN101119976B (zh) | 2005-02-18 | 2010-12-22 | 泰博特克药品有限公司 | 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物 |
| EP1959926A1 (en) | 2005-10-25 | 2008-08-27 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| JP5592647B2 (ja) * | 2006-04-28 | 2014-09-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 制御された析出による６，６−ジメチル−３−アザ−ビシクロ［３．１．０］ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物 |
| CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
| PT2046292E (pt) | 2006-07-21 | 2010-04-26 | Novartis Ag | Formulações de éteres benzimidazolil-piridílicos |
| CN103588704B (zh) * | 2007-03-16 | 2016-09-14 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| US8569298B2 (en) * | 2008-06-17 | 2013-10-29 | Astrazeneca Ab | Pyridine compounds |
| CN102648197A (zh) | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | 促进细胞凋亡和抑制转移的方法 |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 JP JP2013518575A patent/JP5923499B2/ja not_active Expired - Fee Related
- 2011-06-28 NZ NZ60480111A patent/NZ604801A/en not_active IP Right Cessation
- 2011-06-28 MX MX2012014986A patent/MX343894B/es active IP Right Grant
- 2011-06-28 WO PCT/US2011/042169 patent/WO2012012139A1/en not_active Ceased
- 2011-06-28 AU AU2011280031A patent/AU2011280031B2/en not_active Ceased
- 2011-06-28 CN CN2011800421749A patent/CN103168037A/zh active Pending
- 2011-06-28 CA CA2803005A patent/CA2803005A1/en not_active Abandoned
- 2011-06-28 EP EP11810100.5A patent/EP2588476A4/en not_active Withdrawn
-
2013
- 2013-01-02 ZA ZA2013/00012A patent/ZA201300012B/en unknown
- 2013-08-07 US US13/961,517 patent/US9505719B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5923499B2 (ja) | 2016-05-24 |
| NZ604801A (en) | 2015-03-27 |
| WO2012012139A1 (en) | 2012-01-26 |
| EP2588476A4 (en) | 2014-07-23 |
| CA2803005A1 (en) | 2012-01-26 |
| EP2588476A1 (en) | 2013-05-08 |
| JP2013529687A (ja) | 2013-07-22 |
| ZA201300012B (en) | 2013-09-25 |
| US20140235635A1 (en) | 2014-08-21 |
| US9505719B2 (en) | 2016-11-29 |
| CN103168037A (zh) | 2013-06-19 |
| AU2011280031B2 (en) | 2015-09-10 |
| AU2011280031A1 (en) | 2013-01-10 |
| MX2012014986A (es) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348623B (es) | Proceso y sistema de reaccion para la preparacion de metanol. | |
| WO2012054364A3 (en) | Bicyclic diamines as janus kinase inhibitors | |
| EP4223730A3 (en) | Organo-catalytic biomass deconstruction | |
| EP2538979A4 (en) | ADHESIVE COMPOSITE KOAZERVATE MANUFACTURED FROM ELECTROSTATICALLY ASSOCIATED BLOCK COPOLYMERS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| MX2015000129A (es) | Derivados de pirimidin pirazolilo. | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| PH12014502775A1 (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| WO2011090949A3 (en) | Methods and compositions for processing chemical reactions | |
| MX2012003770A (es) | Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia. | |
| EP2582812A4 (en) | NOVEL PHARMACEUTICAL FORMS WITH MODIFIED RELEASE OF XANTHINE OXYDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | |
| WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
| WO2011090694A8 (en) | Orally administrable film dosage forms containing ondansetron | |
| MX350003B (es) | Procedimiento para la fabricación de derivados de dibenzoilmetano. | |
| EP2382434A1 (de) | Verfahren zur thermischen behandlung von zementrohmehl in einem reaktionsraum | |
| ZA201002078B (en) | Bubble column type hydrocarbon synthesis reactor,and hydrocarbon synthesis reaction system having the same | |
| MX2012014986A (es) | Sintesis y uso de inhibidores de cinasa. | |
| IN2012DN00459A (enExample) | ||
| GB201907885D0 (en) | Portable system for the production of oxygen | |
| AP2013007133A0 (en) | Hydrocarbon synthesis reaction apparatus, start-upprocess thereof and hydrocarbon synthesis reactio n system | |
| PH12017500270A1 (en) | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain | |
| BR112014019356A8 (pt) | Método para produzir um ou mais produtos finais de fermentação e produto final de fermentação | |
| GB2489362B (en) | Process for the conversion of synthesis gas | |
| IT1397233B1 (it) | Procedimento migliorativo per la sintesi del mono-acetil ganciclovir, intermedio chiave per la sintesi del valganciclovir. | |
| WO2013184570A3 (en) | Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | |
| ZA201304841B (en) | Use of the reaction product of a hydrocarbyl-substituted dicarboxylic acid and a nitrogen compound for reducing fuel consumption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |